m2p-labs on course for growth

May 30, 2011

m2p-labs reaches break-even point and strengthens growth with new capital

m2p-labs reaches break-even point, thanks to a strong demand for technology in 2010. Strengthened by good sales figures, long-standing investors are now investing in the company’s growth: the Seed Fund for the Region of Aachen GmbH & Co. KG, the KfW with the ERP Start-Up Fund and the High-Tech-Gründerfonds (business start-up fund), as well as two private investors. m2p-labs is a leading provider of innovative screening and fermentation technologies for the pharmaceutical, biotechnical and chemical industries. Its’ product portfolio is subdivided into analysis systems, consumables, automation and culture media. The products, with high throughput and an abundance of online process information, enable the user to accelerate F&E processes significantly.

The considerable expansion of the sales and service team is a central focus of capital increase. Several experienced sales representatives will be employed in the second half of 2011 to promote direct contact with the customer in order to fulfil the customer’s needs more specifically. The number of employees in the company is expected to grow to 11 by the end of 2011.

Due to the company‘s maturation to an established technology supplier for the chemical and pharmaceutical industry, as well as the increase in employees, m2p-labs is also increasing in space. The biotechnological company is underlining this with a move from Aachen to Baesweiler to the International Technology and Service Centre (ITS). “In the ITS we have 350 square metres at our disposal, more than three times the surface area we had before”, Dr. Frank Kensy, managing director of m2p-labs GmbH, now rejoices. A new microtiter plate production and the quality control of instrument production are to be built on the new premises. As well as this there are three laboratories available for microbial and cell cultivation.

“We will use the fresh capital, not only for sales expansion, but also to promote the technological development of new promising products and to invest in their launch onto the market”, emphasises Carsten Müller, managing partner of m2p-labs. The continued development of the BioLector technology for the bioeconomy plays a central role here. “The change of feedstocks in the chemical industry from oil to renewable raw materials requires the use of more biotechnological process steps for the material conversion into new chemical entities”, according to Dr. Frank Kensy. “Innovative technology, such as the BioLector which m2p-labs offers, is necessary for this.” The BioLector allows the online monitoring of cell growth and product formation of new strains already at micro-scale under standardised conditions. In this manner, valuable process information can be gained in high throughput and can make an important contribution to the knowledge-based bioeconomy.

m2p-labs GmbH
m2p-labs is financed by the High-Tech-Gründerfonds (business start-up fund), the KfW and the Seed Fund Aachen. The biotechnology company is specialised in the development of process solutions for cell culture and microbiology in micro-litre scale. The first marketable development is a unique miniature bioreactor system for high content screening. m2p-labs’ special know-how in micro process technology and automation enables the company to offer interested customers contract research or consulting. The company is based in Baesweiler near Aachen, Germany.

m2p-labs GmbH
Dr. Frank Kensy
Managing Director
Phone: +49-(0)2401-805331

Seed Fonds Aachen
The “Seed Fund for the region of Aachen GmbH & Co. KG” is one of six regional business start-up funds which the NRW BANK initiates together with shareholding partners in North Rhine Westphalia. The Seed Fund provides the necessary equity to young technology-oriented companies in the founding phase. The fund can invest a maximum of 850,000 EUR, together with co-investors up to 1.5 million EUR, per company and round of financing. The shareholding experts of the S-UBG AG are behind the operating management of the fund (FM Fund Management for the Region of Aachen Investment GmbH). The investment company of the Sparkassen (savings banks) in the areas of Aachen, Krefeld and Mönchengladbach look back at 20 years of experience in the financing of small businesses and technology-oriented start-ups.

www.seedfonds-aachen.de; www.s-ubg.de

KfW Banking Group’s ERP-Start-Up Fund
The KfW Banking Group finances and supports, among others, entrepreneurs, small and medium-sized enterprises (SME), as well as investments in growth and employment in Germany. Using the EPR Start-Up Funds, which it manages and finances, it participates especially in innovative technology-oriented companies with a particular chance of growth. Research and product development are to be financed alongside the launching of a new product, process or service on the market. The KfW always works together with a lead investor and only in accordance with market conditions. Since 2004, the ERP Start-Up Fund has had a total of ca. 470 m Euro available for investment in young technology companies.


About High-Tech Gründerfonds
High-Tech Gründerfonds invests venture capital in promising technology companies that turn innovative concepts into viable businesses. Seed financing aims to help start-ups guide their innovation to the prototype or proof-of-concept stage or to market launch. High-Tech Gründerfonds provides seed financing of approximately €500,000. It supports high-tech companies by way of its investment managers and its highly-qualified network of coaches, investors and specialists. In individual cases it can invest up to a total of €2 m per company. The investors in this public private partnership are the German Federal Ministry for Business and Technology, the KfW Banking Group as well as the six industrial groups of BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss. High-Tech Gründerfonds has an investment volume totalling approx. €272 m.

High-Tech Gründerfonds Management GmbH
Marco Winzer
Investment Director
Ludwig-Erhard-Allee 2
53175 Bonn
Phone: +49 228 823001-00
Fax: +49 228 823000-50

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

10. July 2024

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today announced the closing of a Series C rou
9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa